☆ 4.7 Article

Assessing treatment outcomes of chemoimmunotherapy in extensive-stage small cell lung cancer: an integrated clinical and radiomics approach

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Molecular Subtypes of Primary SCLC Tumors and Their Associations With Neuroendocrine and Therapeutic Markers

Song Qu et al.

Summary: This study validated a new molecular subtype classification for small cell lung cancer (SCLC) and identified intriguing associations between subtypes and therapeutic markers. It demonstrated significant intratumoral heterogeneity, with different subtypes of tumors exhibiting distinct immunophenotypes.

JOURNAL OF THORACIC ONCOLOGY (2022)

Add to Collection

Article Oncology

Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Jie Wang et al.

Summary: The study evaluated the efficacy and safety of adebrelimab in combination with standard chemotherapy as a first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). The results showed that the addition of adebrelimab significantly improved overall survival and had an acceptable safety profile. Therefore, the combination of adebrelimab and chemotherapy may be a new treatment option for ES-SCLC patients.

LANCET ONCOLOGY (2022)

Add to Collection

Article Oncology

Small cell lung cancer: Subtypes and therapeutic implications

Walter Z. Wang et al.

Summary: Small cell lung cancer (SCLC) is an aggressive tumor with poor understanding of its biology. Recent studies identified four distinct subsets of SCLC and revealed the importance of intratumoral heterogeneity in SCLC development and progression. These findings will inform the design of new therapeutic strategies.

SEMINARS IN CANCER BIOLOGY (2022)

Add to Collection

Article Oncology

Radiation therapy for extensive-stage small-cell lung cancer in the era of immunotherapy

Yaru Tian et al.

Summary: Unlike NSCLC, the progression of SCLC is slow. ES-SCLC poses a serious threat to human health with a low 5-year survival rate. Chemotherapy has been the first-line treatment, but anti-PD-L1 checkpoint blockades have emerged as standard therapy. The combination of radiation therapy and immunotherapy in ES-SCLC has limited evidence and requires further prospective trials.

CANCER LETTERS (2022)

Add to Collection

Article Medicine, General & Internal

Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer The ASTRUM-005 Randomized Clinical Trial

Ying Cheng et al.

Summary: This study evaluated the efficacy and adverse event profile of the PD-1 inhibitor serplulimab plus chemotherapy compared with placebo plus chemotherapy as first-line treatment in patients with extensive-stage SCLC. The results showed that serplulimab plus chemotherapy significantly improved overall survival and progression-free survival compared with chemotherapy alone, supporting its use as a first-line treatment for patients with previously untreated extensive-stage SCLC.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

Add to Collection

Article Oncology

Treatment patterns and outcomes of immunotherapy in extensive-stage small-cell lung cancer based on real-world practice

Yaning Yang et al.

Summary: This study investigated the treatment options and efficacy of immune checkpoint inhibitors (ICIs) in different treatment periods for extensive-stage small-cell lung cancer (ES-SCLC) patients. The results showed that first-line ICIs combined with chemotherapy can prolong progression-free survival (PFS) for ES-SCLC patients. For patients who progressed after first-line treatment, second-line ICIs continuation therapy can also extend PFS. Additionally, second-line ICIs combined therapy can prolong PFS for patients who experienced progression after first-line chemotherapy.

THORACIC CANCER (2022)

Add to Collection

Article Oncology

Prognostic ability of lung immune prognostic index in limited-stage small cell lung cancer

Bochen Sun et al.

Summary: The study aimed to evaluate the role of LIPI in limited-stage SCLC and found that high-risk LIPI was associated with poorer overall survival and progression-free survival. A predictive nomogram based on LIPI was developed with decent predictive power.

BMC CANCER (2022)

Add to Collection

Article Medical Informatics

Mining whole-lung information by artificial intelligence for predicting EGFR genotype and targeted therapy response in lung cancer: a multicohort study

Shuo Wang et al.

Summary: This study introduced a fully automated artificial intelligence system (FAIS) that mined whole-lung information from CT images to predict EGFR genotype and prognosis with EGFR-TKI treatment. FAIS outperformed tumour-based deep learning models, providing a non-invasive method to detect EGFR genotype and identify high-risk EGFR mutation patients for TKI resistance.

LANCET DIGITAL HEALTH (2022)

Add to Collection

Article Oncology

Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities

Carl M. Gay et al.

Summary: Despite the heterogeneity of small cell lung cancer (SCLC), four subtypes have been identified based on tumor expression data, each showing different responses to treatment. SCLC-I subtype benefits the most from immunotherapy, while other subtypes have vulnerabilities to different inhibitors. Matching tumor subtype to therapy and manipulating subtype switching during treatment may enhance response depth and duration for SCLC patients.

CANCER CELL (2021)

Add to Collection

Article Oncology

Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)

Stephen Liu et al.

Summary: IMpower133 trial showed that adding atezolizumab to CP/ET for first-line treatment of ES-SCLC significantly improved patients' overall survival. Atezolizumab demonstrated potential efficacy in treating ES-SCLC.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

What Are the Biomarkers for Immunotherapy in SCLC?

Vito Longo et al.

Summary: Small-cell lung cancer (SCLC) demonstrates limited response to immunotherapy, with only a small number of patients benefiting and a lack of biomarker selection. Research focuses primarily on PD-L1 expression and tumor mutational burden as major biomarkers for immunotherapy, while also exploring other potential biomarkers such as the role of the immune microenvironment in SCLC.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Review Oncology

Immunotherapeutic approaches for small-cell lung cancer

Wade T. Iams et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Harnessing Natural Killer Immunity in Metastatic SCLC

Sarah A. Best et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

Add to Collection

Article Oncology

Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade

Pranjal Vaidya et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Add to Collection

Article Oncology

Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer

C. Allison Stewart et al.

NATURE CANCER (2020)

Add to Collection

Article Oncology

Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer

Triparna Sen et al.

CANCER DISCOVERY (2019)

Add to Collection

Review Medicine, General & Internal

Current Diagnosis and Management of Small-Cell Lung Cancer

Shuhang Wang et al.

MAYO CLINIC PROCEEDINGS (2019)

Add to Collection

Article Medicine, General & Internal

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz-Ares et al.

LANCET (2019)

Add to Collection

Article Immunology

Inducible down-regulation of MHC class I results in natural killer cell tolerance

Michael D. Bern et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2019)

Add to Collection

Article Oncology

A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study

Roger Sun et al.

LANCET ONCOLOGY (2018)

Add to Collection

Article Biochemistry & Molecular Biology

Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning

Nicolas Coudray et al.

NATURE MEDICINE (2018)

Add to Collection

Article Medicine, General & Internal

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

L. Horn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Oncology

Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes

Wei Zhang et al.

TRANSLATIONAL LUNG CANCER RESEARCH (2018)

Add to Collection

Article Multidisciplinary Sciences

Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer

Jing Shan Lim et al.

NATURE (2017)

Add to Collection

Article Oncology

The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer

Andrew G. Nicholson et al.

JOURNAL OF THORACIC ONCOLOGY (2016)

Add to Collection

Review Medicine, General & Internal

Platinum versus non-platinum chemotherapy regimens for small cell lung cancer

Isuru U. Amarasena et al.

COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2015)

Add to Collection

© Peeref 2019-2024. All rights reserved.